Anlon Healthcare Limited has successfully completed a strategic acquisition that strengthens its market position in the healthcare sector. The company announced the completion of acquiring 56.67% equity shareholding in Bizotic Life Science Private Limited on March 20, 2026, under Regulation 30 of the SEBI Listing Regulations.

Acquisition Timeline and Regulatory Compliance

The acquisition follows a structured timeline that began with the execution of a Share Purchase Agreement on November 28, 2025. The company had previously disclosed this development through regulatory filings, maintaining transparency with stakeholders throughout the process.

The transaction was completed well ahead of the extended deadline of April 02, 2026, demonstrating efficient execution of the strategic initiative.

Corporate Structure Impact

Following the successful completion of this acquisition, Bizotic Life Science Private Limited has become a subsidiary of Anlon Healthcare Limited. This development represents a significant expansion of the company's operational footprint and strategic capabilities in the healthcare sector.

Regulatory Framework and Compliance

The acquisition has been structured in full compliance with applicable regulatory requirements:

• SEBI Compliance: Executed under Regulation 30(7) of the SEBI Listing Obligations & Disclosure Requirements Regulations, 2015
• Companies Act Compliance: Adheres to Section 179(3)(e) & (j) and all other applicable provisions of Companies Act, 2013
• Disclosure Requirements: All mandatory details were provided in the initial disclosure dated November 28, 2025, as per SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Strategic Significance

This acquisition marks an important step in Anlon Healthcare Limited's growth strategy, expanding its presence through the addition of Bizotic Life Science Private Limited as a subsidiary. The transaction demonstrates the company's commitment to strategic expansion while maintaining strict adherence to regulatory compliance and transparency standards.

The completion of this acquisition positions Anlon Healthcare Limited for enhanced operational capabilities and market reach through its newly acquired subsidiary, Bizotic Life Science Private Limited.

Anlon healthcare Limited has announced a scheduled analyst and investor meeting with S. N. Damani Group for March 21, 2026. The company filed the disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, maintaining compliance with regulatory transparency requirements.

Meeting Details and Format

The interaction will be conducted as a physical meeting at the company's Rajkot facility, featuring both a plant visit and management discussion. Chairman and Managing Director Punikumar Rasadia will lead the engagement with the analyst group.

Regulatory Compliance and Information Guidelines

The company has emphasized that all discussions during the meeting will be based exclusively on publicly available information and documents. No unpublished price-sensitive information (UPSI) will be discussed during the interactions, ensuring full compliance with regulatory guidelines.

The meeting schedule remains subject to potential changes, with the company noting that discussions may be cancelled, rescheduled, or postponed due to exigencies from either party. This flexibility ensures both parties can accommodate any unforeseen circumstances while maintaining the planned engagement framework.

Corporate Communication Framework

The disclosure demonstrates Anlon Healthcare's commitment to maintaining transparent investor relations and regulatory compliance. The structured approach to analyst interactions, combined with clear guidelines on information sharing, reflects the company's adherence to corporate governance standards in investor communications.